Page last updated: 2024-08-22

vidarabine and Autosomal Chromosome Disorders

vidarabine has been researched along with Autosomal Chromosome Disorders in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S	1
Marlton, P; McCarthy, C; Taylor, K	1
Beran, M; Childs, C; Huh, Y; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Schachner, J	1

Trials

1 trial(s) available for vidarabine and Autosomal Chromosome Disorders

Article	Year
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. The American journal of medicine, 1991, Volume: 90, Issue:2 Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Chromosome Aberrations; Chromosome Disorders; Female; Humans; Immunoglobulin M; Karyotyping; Leukemia, Prolymphocytic; Male; Middle Aged; Prednisone; Remission Induction; Vidarabine	1991

Article

Year

Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.

The American journal of medicine, 1991, Volume: 90, Issue:2

Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Chromosome Aberrations; Chromosome Disorders; Female; Humans; Immunoglobulin M; Karyotyping; Leukemia, Prolymphocytic; Male; Middle Aged; Prednisone; Remission Induction; Vidarabine

1991

Other Studies

2 other study(ies) available for vidarabine and Autosomal Chromosome Disorders

Article	Year
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines and molecular therapy, 1995, Volume: 1, Issue:1 Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine	1995
Fludarabine-induced cytogenetic remission in prolymphocytic leukemia. American journal of hematology, 1992, Volume: 40, Issue:1 Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Humans; Karyotyping; Leukemia, Prolymphocytic; Male; Vidarabine	1992

Article

Year

High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).

Cytokines and molecular therapy, 1995, Volume: 1, Issue:1

Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine

1995

Fludarabine-induced cytogenetic remission in prolymphocytic leukemia.

American journal of hematology, 1992, Volume: 40, Issue:1

Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Humans; Karyotyping; Leukemia, Prolymphocytic; Male; Vidarabine

1992